SinoMab FY26 H1 loss widens to RMB 127.4 million; funding available drops to RMB 196.5 millionPUBT·6 hours ago03681+2.33%
Strategy on the Periphery: Navigating Paradigm Shifts in Hong Kong EquitiesGlobal Report·Aug 25 at 06:32 AM03681+2.33%017120.00%
Biotech Ambitions and Travel Takeovers: Moves Reshaping Hong Kong's Mixed EquitiesGlobal Report·Aug 25 at 04:20 AM03692-3.76%03681+2.33%
SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 MillionTip Ranks·Aug 20 at 05:37 PM03681+2.33%
SinoMab BioScience schedules board meeting to review interim resultsPUBT·Aug 19 at 06:04 AM03681+2.33%
SinoMab BioScience sets Sept. 7 shareholder vote on proposed Suzhou property, facility salePUBT·Aug 18 at 08:05 AM03681+2.33%
SinoMab BioScience files list of directors, board committee memberships and disclosure-responsible managementPUBT·Aug 18 at 05:45 AM03681+2.33%
The Misfit Toys of Hong Kong Equities: Who is Actually Working and Who is Faking ItGlobal Report·Aug 13 at 04:43 AM02005+0.37%015460.00%
SinoMab BioScience to sell Suzhou property, facility for RMB 280 millionPUBT·Jul 6 at 06:19 AM03681+2.33%
SinoMab BioScience files board, board committee and management disclosure listPUBT·Jul 3 at 06:25 AM03681+2.33%
SinoMab Bioscience Clarifies Board Structure and Committee RolesTip Ranks·Jun 12 at 10:10 AM03681+2.33%
